-
23 July 2025 07:01:18
- Source: Sharecast
Diaceutics PLC
("Diaceutics" or the "Company")
Issue of Share Options/PDMR Shareholdings
New York, Belfast and London, 23 July 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the issue of 1,886,357 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.
Share Options were granted as follows:
|
Name |
Number of Share Options granted |
Total no. of ordinary shares under option post grant |
% of existing issued share capital |
Performance Period |
|
Ryan Keeling, CEO
|
271,688 |
1,339,298 |
1.58% |
3 years from 22 July 2025 |
|
Nick Roberts, CFO
|
194,063 |
619,335 |
0.73% |
3 years from 22 July 2025 |
|
Jordan Clark, CDO
|
189,750 |
329,497 |
0.39% |
3 years from 22 July 2025
|
|
Jillian Beggs, CCO and PDMR |
83,771 |
188,851 |
0.22% |
3 years from 22 July 2025
|
|
Sandra Blake, CPO and PDMR |
86,250 |
162,586 |
0.19% |
3 years from 22 July 2025
|
|
Susanne Munksted, CPMO and PDMR |
88,187 |
323,423 |
0.38% |
3 years from 22 July 2025
|
|
Other employees (64 persons) |
972,648 |
3,248,476 |
3.83% |
3 years from 22 July 2025
|
For the Executive Directors, Jordan Clark, Ryan Keeling and Nick Roberts, the Share Options vest on a sliding scale up to 100%, where vesting is subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return ("TSR"), the revenue Compound Annual Growth Rate ("CAGR") and Adjusted EBITDA Margin. For all other employees, the Share Options vest after three years from the date of grant dependent upon continual employment and satisfactory employee performance.
The Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate, having regard to overall Company performance and wider shareholder experience.
The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.
Following this grant, the total number of share options outstanding in the Company is 6,211,466 representing approximately 7.32% of its current issued share capital of 84,812,636.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a. |
Name |
1. Ryan Keeling |
CEO |
||
|
2. Nick Roberts |
CFO |
||||
|
3. Jordan Clark |
CDO |
||||
|
4. Jillian Beggs |
CCO |
||||
|
5. Sandra Blake |
CPO |
||||
|
6. Susanne Munksted |
CPMO |
||||
|
2 |
Reason for notification |
|
|||
|
a. |
Position/Status |
As above |
|||
|
b. |
Initial notification/ Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a. |
Name |
Diaceutics plc |
|||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of 0.2p each
|
|||
|
b. |
Identification Code |
ISIN: GB00BJQTGV64 |
|||
|
c. |
Nature of the transaction |
Grant of share options |
|||
|
d. |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
1. |
Exercise price of 0.2p per share |
271,688 |
|||
|
2. |
Exercise price of 0.2p per share |
194,063 |
|||
|
3. |
Exercise price of 0.2p per share |
189,750 |
|||
|
4. |
Exercise price of 0.2p per share |
83,771 |
|||
|
5. |
Exercise price of 0.2p per share |
86,250 |
|||
|
6. |
Exercise price of 0.2p per share |
88,187 |
|||
|
e. |
Date of the transaction |
22 July 2025 |
|||
|
f. |
Place of the transaction |
Outside a trading venue |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.